Tag: neoantigen

1 predictions tagged with "neoantigen".

Moderna And Merck's Personalized MRNA Neoantigen Cancer Vaccine Intismeran Autogene (V940/mRNA-4157) Is Expected To Receive Its First Regulatory Approval In 2028 As Adjuvant Treatment For High-risk Melanoma.